Beaver Run Conference Center Floorplan
This meeting took place in 2018
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
T Cell Dysfunction, Cancer and Infection (A3)
Organizer(s) Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok
January 16—20, 2018
Beaver Run Conference Center • Breckenridge, CO USA
Discounted Abstract Deadline: Sep 21, 2017
Abstract Deadline: Oct 19, 2017
Scholarship Deadline: Sep 21, 2017
Discounted Registration Deadline: Nov 20, 2017
Sponsored by Amgen Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology and TESARO, Inc.
Summary of Meeting:
T cell exhaustion is an acquired state of T cell dysfunction, associated with reduced T cell function, sustained expression of inhibitory receptors and a transcriptional state that is distinct from memory and effector T cells. T cell exhaustion is now recognized as a defining feature not only of chronic infections such as HIV, malaria and tuberculosis, but also of cancer. As a result, the search for effective approaches to reverse T cell exhaustion is the focus of immense therapeutic development. However, the similarities and differences between T cell dysfunction arising in chronic infection and tumors are not fully understood. Moreover, opportunities to identify new therapeutic approaches to reverse dysfunction based on parallels between the two disease states remain to be explored. This meeting will focus on the comparative biology and clinical therapeutics of T cell dysfunction in chronic viral infection and cancer. Drawing on leaders in fundamental T cell biology, computational science and clinical investigation, it will focus on common features and distinctive aspects of T cell dysfunction in cancer and chronic infection. The meeting will have broad relevance for T cell biology, tumor immunity, infectious disease and therapeutic development.
View Scholarships/Awards
T cell exhaustion is an acquired state of T cell dysfunction, associated with reduced T cell function, sustained expression of inhibitory receptors and a transcriptional state that is distinct from memory and effector T cells. T cell exhaustion is now recognized as a defining feature not only of chronic infections such as HIV, malaria and tuberculosis, but also of cancer. As a result, the search for effective approaches to reverse T cell exhaustion is the focus of immense therapeutic development. However, the similarities and differences between T cell dysfunction arising in chronic infection and tumors are not fully understood. Moreover, opportunities to identify new therapeutic approaches to reverse dysfunction based on parallels between the two disease states remain to be explored. This meeting will focus on the comparative biology and clinical therapeutics of T cell dysfunction in chronic viral infection and cancer. Drawing on leaders in fundamental T cell biology, computational science and clinical investigation, it will focus on common features and distinctive aspects of T cell dysfunction in cancer and chronic infection. The meeting will have broad relevance for T cell biology, tumor immunity, infectious disease and therapeutic development.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Tuesday, January 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, January 20 with a closing plenary session and keynote address from 17:00 to 19:15, followed by a social hour and entertainment. We recommend return travel on Sunday, January 21 in order to fully experience the meeting.
TUESDAY, JANUARY 16
WEDNESDAY, JANUARY 17
THURSDAY, JANUARY 18
FRIDAY, JANUARY 19
SATURDAY, JANUARY 20
SUNDAY, JANUARY 21
Conference Program Print | View meeting in 24 hr (international) time
The meeting will begin on Tuesday, January 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, January 20 with a closing plenary session and keynote address from 17:00 to 19:15, followed by a social hour and entertainment. We recommend return travel on Sunday, January 21 in order to fully experience the meeting.
TUESDAY, JANUARY 16
8:00—9:00 AM
Welcome and Keynote Address
*
Daniel C. Douek,
NIAID, National Institutes of Health, USA
Session Chair
Session Chair
*
W. Nicholas Haining,
Merck Research Laboratories, USA
Session Chair
Session Chair
Rafi Ahmed,
Emory University School of Medicine, USA
A New Look at T Cell Exhaustion
A New Look at T Cell Exhaustion
9:00—11:30 AM
Adoptive T Cell Therapy for Cancer
*
Susan M. Kaech,
The Salk Institute, USA
Session Chair
Session Chair
Crystal L. Mackall,
Stanford University, USA
Use of Adoptive T Cell Transfer in Pediatric Patients
Use of Adoptive T Cell Transfer in Pediatric Patients
Coffee Break
Cassian Yee,
University of Texas MD Anderson Cancer Center, USA
Endogenous T Cell Therapy: Finding Dory
Endogenous T Cell Therapy: Finding Dory
Michael C. Jensen,
Seattle Children's Research Institute, USA
Overcoming Barriers to Achieving Curative Outcomes Following CD19CAR T Cell Therapy For Recurrent/Refractory Pediatric ALL
Overcoming Barriers to Achieving Curative Outcomes Following CD19CAR T Cell Therapy For Recurrent/Refractory Pediatric ALL
Cyrille J. Cohen,
Bar-Ilan University, Israel
Short Talk: Improved Targeting of Multiple Tumors and Viral-Infected Cells using T-Cells Engineered to Express NCR-Based Chimeric Receptors
Short Talk: Improved Targeting of Multiple Tumors and Viral-Infected Cells using T-Cells Engineered to Express NCR-Based Chimeric Receptors
Lexus Johnson,
University of Pennsylvania, USA
Short Talk: Intratumoral Immune Activation Informs Rational CAR T Cell Design
Short Talk: Intratumoral Immune Activation Informs Rational CAR T Cell Design
5:00—7:00 PM
T Cells and their Microenvironment
*
W. Nicholas Haining,
Merck Research Laboratories, USA
Session Chair
Session Chair
Daniel C. Douek,
NIAID, National Institutes of Health, USA
Influence of the Systemic Microbiome on Inflammation During HIV Infection
Influence of the Systemic Microbiome on Inflammation During HIV Infection
David G. Brooks,
Princess Margaret Cancer Center, Canada
Type I Interferons and Inflammation in T Cell Immunity
Type I Interferons and Inflammation in T Cell Immunity
Susan M. Kaech,
The Salk Institute, USA
Anti-Tumor T Cells: You Are What You Eat
Anti-Tumor T Cells: You Are What You Eat
Rafick Sekaly,
Emory University, USA
Short Talk: PD-1 and IL-1 Control Two Independent Mechanisms of Immune Dysfunction and Response to Treatment in Cancer and HIV
Short Talk: PD-1 and IL-1 Control Two Independent Mechanisms of Immune Dysfunction and Response to Treatment in Cancer and HIV
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:15 AM
Basic Biology of T Cell Exhaustion
*
E. John Wherry,
University of Pennsylvania, USA
Session Chair
Session Chair
W. Nicholas Haining,
Merck Research Laboratories, USA
The Epigenetic Landscape of T Cell Exhaustion
The Epigenetic Landscape of T Cell Exhaustion
Ananda W. Goldrath,
University of California, San Diego, USA
Transcriptional Regulation of CD8 T Cell Immunity
Transcriptional Regulation of CD8 T Cell Immunity
Coffee Break
Andrea Schietinger,
Memorial Sloan Kettering Cancer Center, USA
Tumor-Specific T Cell Dysfunction
Tumor-Specific T Cell Dysfunction
Dietmar Zehn,
Technical University of Munich, Germany
Subsets and T Cell Differentiation in Chronic LCMV Infection
Subsets and T Cell Differentiation in Chronic LCMV Infection
Curtis H. Cai,
University of New South Wales, Australia
Short Talk: Elucidating the Factors Associated with Dysfunctional T-cell Responses in HCV Infection using scRNA-seq and Functional Analyses
Short Talk: Elucidating the Factors Associated with Dysfunctional T-cell Responses in HCV Infection using scRNA-seq and Functional Analyses
Jennifer M. Dan,
University of California, San Diego, USA
Short Talk: Recurrent Group A Streptococcus Tonsillitis Is a Genetic Immunosusceptibility Disease with Aberrant Follicular Helper CD4+ T Cells
Short Talk: Recurrent Group A Streptococcus Tonsillitis Is a Genetic Immunosusceptibility Disease with Aberrant Follicular Helper CD4+ T Cells
5:00—7:00 PM
Adoptive T Cell Transfer for Infection
*
Robert Thimme,
University Medical Center Freiburg, Germany
Session Chair
Session Chair
Philip D. Greenberg,
University of Washington, USA
Novel Approaches to Isolating Receptors and Engineering Cells to Target Tumor Antigens
Novel Approaches to Isolating Receptors and Engineering Cells to Target Tumor Antigens
James L. Riley,
University of Pennsylvania, USA
Engineering T Cells to Functionally Cure HIV-1 Infection
Engineering T Cells to Functionally Cure HIV-1 Infection
Catherine M. Bollard,
Children’s National Health System, USA
Virus-Specific T Cells Post HSCT- Broadening Applicability
Virus-Specific T Cells Post HSCT- Broadening Applicability
Sanjivan Sanjivan Gautam,
NCI, National Institutes of Health, USA
Short Talk: The Transcription Factor Myb Enhances CD8+ T Cell Memory and Anti-Tumor Function by Inducing Tcf7 and Restraining Zeb2 Transcription
Short Talk: The Transcription Factor Myb Enhances CD8+ T Cell Memory and Anti-Tumor Function by Inducing Tcf7 and Restraining Zeb2 Transcription
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:15 AM
Basic Biology of Inhibitory Receptors
*
Rafick Sekaly,
Emory University, USA
Session Chair
Session Chair
Dario A. A. Vignali,
University of Pittsburgh School of Medicine, USA
LAG3: Function, Mode of Action and its Impact on Cancer Immunotherapy
LAG3: Function, Mode of Action and its Impact on Cancer Immunotherapy
Coffee Break
Sadna Budhu,
Memorial Sloan Kettering Cancer Center, USA
Blockade of Surface-Bound TGF-β on Regulatory T Cells Abrogates Suppression of Effector T Cell Function in the Tumor Microenvironment
Blockade of Surface-Bound TGF-β on Regulatory T Cells Abrogates Suppression of Effector T Cell Function in the Tumor Microenvironment
Ira Mellman,
Genentech, Inc., USA
PD-L1 Blockade and Targeted Therapy
PD-L1 Blockade and Targeted Therapy
Frédéric Duval,
University of Montreal, Canada
Short Talk: Notch Signaling Dampens Cd8 T Cell Exhaustion During Chronic Infection
Short Talk: Notch Signaling Dampens Cd8 T Cell Exhaustion During Chronic Infection
Hazem E. Ghoneim,
St Jude Children's Research Hospital, USA
Short Talk: Inhibiting Exhaustion-Associated Epigenetic Programs Enhances PD-1 Blockade-Mediated T Cell Rejuvenation
Short Talk: Inhibiting Exhaustion-Associated Epigenetic Programs Enhances PD-1 Blockade-Mediated T Cell Rejuvenation
5:00—7:00 PM
Checkpoint Blockade
*
Daniel C. Douek,
NIAID, National Institutes of Health, USA
Session Chair
Session Chair
Roberta Zappasodi,
Memorial Sloan-Kettering Cancer Center, USA
Non-conventional Immunosuppressive TFH-like CD4+ T Cells Promote Resistance to Immune Checkpoint Blockade Therapy
Non-conventional Immunosuppressive TFH-like CD4+ T Cells Promote Resistance to Immune Checkpoint Blockade Therapy
Suzanne L. Topalian,
Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Virus-Associated Cancers: Intersection of Antitumor Immunity and Infectious Immunity
PD-1 Blockade in Virus-Associated Cancers: Intersection of Antitumor Immunity and Infectious Immunity
E. John Wherry,
University of Pennsylvania, USA
T Cell Exhaustion and Immunotherapy
T Cell Exhaustion and Immunotherapy
Rebecca Dookie,
University of Manchester, UK
Short Talk: Investigating the Role of Checkpoint Inhibitors in Malaria-Induced T Cell Exhaustion
Short Talk: Investigating the Role of Checkpoint Inhibitors in Malaria-Induced T Cell Exhaustion
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 AM
Targets for T Cells
*
Robert A. Seder,
NIAID, National Institutes of Health, USA
Session Chair
Session Chair
Robert Thimme,
University Medical Center Freiburg, Germany
Impact of Antigen Recognition on T Cell Diversification in Chronic Viral Hepatitis
Impact of Antigen Recognition on T Cell Diversification in Chronic Viral Hepatitis
Pramod K. Srivastava,
University of Connecticut School of Medicine, USA
Broadening the View of Mutational Antigens for Cancer Immunotherapy
Broadening the View of Mutational Antigens for Cancer Immunotherapy
Coffee Break
Lélia Delamarre,
Genentech, Inc., USA
Determinants of Cancer Neoantigen Immunogenicity
Determinants of Cancer Neoantigen Immunogenicity
Brendan Bulik-Sullivan,
Gritstone Oncology, USA
Short Talk: Antigen Identification for Cancer Immunotherapy by Deep Learning on Tumor HLA Peptides
Short Talk: Antigen Identification for Cancer Immunotherapy by Deep Learning on Tumor HLA Peptides
Thomas Duhen,
Agonox, USA
Short Talk: Co-Expression of CD39 and CD103 Identifies Tumor-Reactive CD8 TIL in Human Solid Tumors
Short Talk: Co-Expression of CD39 and CD103 Identifies Tumor-Reactive CD8 TIL in Human Solid Tumors
5:00—6:15 PM
Vaccines to Revive T Cell Responses
*
Dario A. A. Vignali,
University of Pittsburgh School of Medicine, USA
Session Chair
Session Chair
Robert A. Seder,
NIAID, National Institutes of Health, USA
Adjuvants for T Cell Vaccines
Adjuvants for T Cell Vaccines
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Boosting T Cells by Getting Vaccines Where They Need to Go
Boosting T Cells by Getting Vaccines Where They Need to Go
6:15—7:00 PM
Closing Keynote Address
*
Daniel C. Douek,
NIAID, National Institutes of Health, USA
Session Chair
Session Chair
Carl H. June,
University of Pennsylvania, USA
Enhancing Engineered T Cell Therapy for Cancer
Enhancing Engineered T Cell Therapy for Cancer
7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
